Latest News for CRIS
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.11 per share a year ago.
Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript
Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.
INGOLSTADT, Germany--(BUSINESS WIRE)--SecurityBridge, a leading provider of cybersecurity solutions for SAP, today announced the release of the Cybersecurity Resilience Index for SAP (CRIS), an industry benchmarking report that analyzes how organizations running SAP are securing their environments. The report is a timely response to global security incidents involving SAP environments that provides organizations…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CRIS.
U.S. House Trading
No House trades found for CRIS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.